Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label Extension Trial of tMG to Evaluate the Safety and Efficacy of Tocilizumab in Subjects With Generalized Myasthenia Gravis (gMG)

NCT05716035 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT05716035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05716035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label Extension Trial of tMG to Evaluate the Safety and Efficacy of Tocilizumab in Subjects With Generalized Myasthenia Gravis (gMG)
Lead sponsor
Tang-Du Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 1, 2023
Completion date
December 31, 2024
Enrollment
64 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized